Published in Ann Intern Med on May 16, 2006
Combination Therapy for Chronic Hepatitis C Infection | NCT01805882
GS-7977 With Ribavirin for Hepatitis C (SPARE) | NCT01441180
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C | NCT00475176
Hepatitis C Virus(HCV) Heart and Lung Study | NCT02858180
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV | NCT01443923
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1 | NCT00735969
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 7.36
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med (2014) 3.50
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol (2007) 3.04
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol (2014) 2.85
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer (2015) 2.67
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology (2010) 2.64
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology (2012) 2.59
Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev (2009) 2.50
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology (2011) 2.42
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39
A Canadian screening program for hepatitis C: is now the time? CMAJ (2013) 2.33
Toll-like receptors as targets in chronic liver diseases. Gut (2009) 2.29
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother (2008) 2.22
Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther (2014) 2.18
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology (2014) 2.17
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther (2013) 2.15
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13
Hepatitis C treatment completion rates in routine clinical care. Liver Int (2009) 2.10
Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest (2008) 2.08
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc (2009) 2.07
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol (2007) 1.86
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology (2009) 1.80
Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico. Public Health Rep (2007) 1.73
AN OVERVIEW OF ELASTOGRAPHY - AN EMERGING BRANCH OF MEDICAL IMAGING. Curr Med Imaging Rev (2011) 1.73
The epidemiology of hepatitis C infection in the United States. J Gastroenterol (2007) 1.71
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One (2014) 1.69
Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology (2009) 1.63
Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am (2007) 1.63
Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf (2009) 1.61
Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis (2013) 1.61
Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend (2008) 1.60
Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics (2010) 1.60
The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One (2014) 1.58
Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther (2011) 1.57
Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene (2011) 1.56
Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep (2014) 1.55
National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev Chronic Dis (2008) 1.55
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology (2014) 1.54
The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One (2015) 1.51
Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol (2011) 1.48
Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology (2012) 1.47
Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use. Dig Dis Sci (2011) 1.47
Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. Hepatology (2011) 1.47
The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol (2008) 1.46
HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology (2014) 1.46
Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico. BMC Infect Dis (2010) 1.45
Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology (2015) 1.44
U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients. Dig Dis Sci (2011) 1.44
An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis (2013) 1.42
Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. Proc Natl Acad Sci U S A (2013) 1.42
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat (2008) 1.40
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc (2014) 1.38
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV. J Mol Biol (2010) 1.38
Texas statewide hepatitis C counseling and testing, 2000-2005. Public Health Rep (2007) 1.37
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci (2010) 1.35
RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. RNA (2010) 1.35
HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmun (2008) 1.35
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology (2009) 1.35
Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol (2006) 1.33
The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci (2007) 1.33
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat (2010) 1.31
Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant (2011) 1.31
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Racial differences in hepatitis C treatment eligibility. Hepatology (2011) 1.28
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology (2010) 1.28
Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis (2013) 1.26
IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One (2012) 1.25
Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS (2009) 1.25
Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf (2012) 1.24
Sampling and recruitment in multilevel studies among marginalized urban populations: the IMPACT studies. J Urban Health (2008) 1.23
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction (2008) 1.20
Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Public Health Rep (2012) 1.18
Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res (2007) 1.18
Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L. Virus Res (2007) 1.18
Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev (2009) 1.17
PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep (2013) 1.17
Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling. J Virol (2012) 1.17
Current and future disease progression of the chronic HCV population in the United States. PLoS One (2013) 1.17
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA (2006) 7.46
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep (2008) 6.02
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep (2005) 5.70
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep (2006) 5.63
Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev (2006) 5.13
Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med (2007) 4.64
Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep (2003) 3.96
Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics (2009) 3.87
Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2006) 3.77
Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med (2014) 3.50
Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis (2002) 3.42
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
Seroprevalence of six infectious diseases among adults in the United States by race/ethnicity: data from the third national health and nutrition examination survey, 1988--94. Adv Data (2005) 2.95
Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ (2009) 2.69
Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis (2009) 2.62
Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology (2012) 2.59
The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis (2010) 2.52
Hepatitis C virus transmission from an anesthesiologist to a patient. Arch Intern Med (2002) 2.11
AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood (2010) 2.10
Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis (2002) 2.06
Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis (2005) 1.90
Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis (2007) 1.88
Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis (2013) 1.80
National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial (2005) 1.75
Seroprevalence of antibody to mumps virus in the US population, 1999-2004. J Infect Dis (2010) 1.70
Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis (2006) 1.57
Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology (2006) 1.55
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol (2011) 1.48
Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol (2003) 1.48
The increasing burden of imported chronic hepatitis B--United States, 1974-2008. PLoS One (2011) 1.37
Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med (2011) 1.35
Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine (2005) 1.31
Ongoing transmission of hepatitis B virus infection among inmates at a state correctional facility. Am J Public Health (2005) 1.28
Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol (2007) 1.25
The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol (2006) 1.25
Interim Guidance for Interpretation of Zika Virus Antibody Test Results. MMWR Morb Mortal Wkly Rep (2016) 1.23
Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology (2006) 1.23
Evaluation of screening criteria to identify persons with hepatitis C virus infection among sexually transmitted disease clinic clients: results from the San Diego Viral Hepatitis Integration Project. Sex Transm Dis (2003) 1.21
Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999-2004. Public Health Rep (2010) 1.14
Seroprevalence of HIV in the US Household Population Aged 18–49 Years: The National Health and Nutrition Examination Surveys, 1999–2006. J Acquir Immune Defic Syndr (2010) 1.11
Prevalence of syphilis seroreactivity in the United States: data from the National Health and Nutrition Examination Surveys (NHANES) 2001-2004. Sex Transm Dis (2008) 1.10
Hepatitis B vaccination coverage levels among healthcare workers in the United States, 2002-2003. Infect Control Hosp Epidemiol (2007) 1.06
SARS surveillance during emergency public health response, United States, March-July 2003. Emerg Infect Dis (2004) 1.03
Global invasive bacterial vaccine-preventable diseases surveillance--2008-2014. MMWR Morb Mortal Wkly Rep (2014) 0.99
National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial (2004) 0.99
Parental knowledge, attitudes, and practices associated with not receiving hepatitis A vaccine in a demonstration project in Butte County, California. Pediatrics (2003) 0.99
Seroprevalence of HCV infection in homeless Baltimore families. J Health Care Poor Underserved (2008) 0.99
Seroprevalence of hepatitis A virus antibodies in the U.S.: results from the National Health and Nutrition Examination Survey. Public Health Rep (2011) 0.91
Healthcare should not be a vehicle for transmission of hepatitis C virus. J Hepatol (2007) 0.91
National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial (2002) 0.91
Factors associated with personal protection equipment use and hand hygiene among hemodialysis staff. Am J Infect Control (2006) 0.91
Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination. Pediatrics (2006) 0.91
Hepatitis A incidence and hepatitis a vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health (2004) 0.90
Did CDC's 2006 revised HIV testing recommendations make a difference? Evaluation of HIV testing in the US household population, 2003-2010. J Acquir Immune Defic Syndr (2014) 0.89
WHO global rotavirus surveillance network: a strategic review of the first 5 years, 2008-2012. MMWR Morb Mortal Wkly Rep (2014) 0.88
Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993-2007. Cancer Causes Control (2012) 0.88
Prevalence and risk factors for bloodborne exposure and infection in correctional healthcare workers. Infect Control Hosp Epidemiol (2006) 0.86
Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine (2011) 0.83
Cancers attributable to infections among adults with HIV in the United States. AIDS (2015) 0.82
Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 0.81
Relationship of sex steroid hormones with body size and with body composition measured by dual-energy X-ray absorptiometry in US men. Cancer Causes Control (2012) 0.80
Estimating the number of births to hepatitis B virus-infected women in 22 states, 2006. Pediatr Infect Dis J (2011) 0.80
Blood exposures and hepatitis C virus infections among emergency responders. Arch Intern Med (2003) 0.80
Prevalence and risk factors for hepatitis C virus infection among adolescents in detention. Arch Pediatr Adolesc Med (2005) 0.80
Transforming strategies for the prevention of chronic HBV and HCV infections. J Fam Pract (2010) 0.79
Integrating risk history screening and HCV testing into clinical and public health settings. Am Fam Physician (2005) 0.79
Unequal access to vaccines in the WHO European Region during the A(H1N1) influenza pandemic in 2009. Vaccine (2013) 0.79
Positive impact of a shelter-based hepatitis B vaccine program in homeless Baltimore children and adolescents. J Urban Health (2008) 0.78
Tetanus and diphtheria immunity among females in the United States: are recommendations being followed? Am J Obstet Gynecol (2004) 0.78
Infection with hepatitis C virus among HIV-infected pregnant women in Thailand. Infect Dis Obstet Gynecol (2009) 0.78
Occupational exposures and risk of hepatitis B virus infection among public safety workers. J Occup Environ Med (2002) 0.78
Hepatitis C virus infection in Samoa and American Samoa. Am J Trop Med Hyg (2006) 0.77
Perinatal hepatitis C virus transmission--role of human immunodeficiency virus infection and injection drug use. J Infect Dis (2003) 0.75
National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014. Vital Health Stat 2 (2015) 0.75
Trends in liver cancer, Sa Kaeo Province Thailand. Asian Pac J Cancer Prev (2005) 0.75